IDH1 and cholangiocarcinoma: This is particularly relevant since IDH mutations were shown to have an immunosuppressive effect, both in CCA and other tumours [38, 39], but so far this was not confirmed in subgroup analyses of clinical trials [40] nor in real‐world data [41], where IDH1 mutations were not associated with a different outcome of chemo‐immunotherapy.